The goal of this observational study is to:

• To confirm the continued performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 3 months post-pigmentation;
• To confirm the continued safety of BIOCHROMADERM®,
• To confirm adequate usability and describe the optimal process for BIOCHROMADERM® implantation
• To assess the long-term performance of BIOCHROMADERM® in restoring a near-normal pigmentary appearance of the nipple-areola complex at 12 months post-pigmentation (Likert scale)
• To assess the evolution of performance (Likert scale) between baseline, 3 months and 12 months post-pigmentation
• To assess fading (pigment retention potential) over 12 months
• To assess the number of pigmentation adjustments needed per patient throughout the study duration
• To assess patient's satisfaction/self-confidence evolution post-treatment, both in terms of general breast appearance and as to the specific dermo-pigmentation stage
• To assess the correlation of the esthetic satisfaction/self-confidence questionnaire outcomes with those of the Likert Scale and patient satisfaction VAS at 3 months and 12 months post-pigmentation

Inclusion Criteria:

• Female or male ≥18 years old,
• Requiring the reconstruction of the nipple-areola complex following mastectomy,
• Affiliated or beneficiary of a social security scheme,
• Able and willing to provide written informed consent to study participation.

Exclusion Criteria:

• Known allergy to pigment ingredients
• Active, recent or prior history of skin disease, chronic skin disease, history of hypertrophic scars, skin infection or skin inflammatory disease,
• Patients carrying a prosthesis (especially cardiac),
• Patients presenting with a coagulation disorder,
• Patients scheduled for an MRI within 6 months following pigmentation,
• Patients scheduled for a skin esthetic treatment close to the pigmentation zone (laser, peeling, abrasion, ...) shortly after pigmentation,
• Existing medical condition or organ pathology close to the skin that the Investigator considers may put the patient at risk or compromise their participation in the study,
• Pregnant or breastfeeding female,
• Currently participating to another clinical trial or having participated to a prior clinical trial within 1 month prior to inclusion into the present one,
• Personal strong objection to medical tattooing,
• Psychiatric illness/social situations that would limit ability to consent and/or to compliance with study requirements,
• Under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision.

Note: The recent use of permanent wrinkle or lip filling products close to the scheduled pigmentation zone (silicon, PTFE, ...) is a contraindication in the approved product IFU but is not relevant to the breast reconstruction indication.

Adult patients requiring the correction of skin pigmentation in the NAC area as a result of breast reconstructive surgery following mastectomy.

Up to 115 patients will be included into the study by 3 clinical sites, in order to obtain 103 treated patients followed up over 12 months post-procedure per protocol